Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Apr 8;16(4):e0249972.
doi: 10.1371/journal.pone.0249972. eCollection 2021.

Evaluation of rapid SARS-CoV-2 antigen tests, AFIAS COVID-19 Ag and ichroma COVID-19 Ag, with serial nasopharyngeal specimens from COVID-19 patients

Affiliations
Clinical Trial

Evaluation of rapid SARS-CoV-2 antigen tests, AFIAS COVID-19 Ag and ichroma COVID-19 Ag, with serial nasopharyngeal specimens from COVID-19 patients

Oh Joo Kweon et al. PLoS One. .

Abstract

We evaluated the diagnostic accuracy of two newly developed, point-of-care, rapid antigen tests (RATs) for detecting SARS-CoV-2, the AFIAS COVID-19 Ag and the ichromaTM COVID-19 Ag, and investigated antigen kinetics. A total of 200 serially collected nasopharyngeal (NP) specimens from 38 COVID-19 patients and 122 specimens from negative controls were analyzed. Diagnostic sensitivity and specificity were assessed in comparison to molecular test results and subdivided according to targeted genes (E, RdRP, and N) and days post-symptom onset (PSO). For the kinetics evaluation, cut-off-indices from serial NP specimens were used according to the number of days PSO. Both RATs showed sensitivity of 91.3‒100% for specimens with cycle threshold (Ct) < 25. The specificity of AFIAS was 98.7‒98.9% and that of ichromaTM was 100.0%. The kappa values of AFIAS and ichromaTM for the molecular testing of specimens with Ct < 25 (RdRP) were 0.97 and 1.00, respectively. The sensitivity of AFIAS and ichromaTM for all genes was lower for specimens collected at 8‒14 PSO than for those collected before 7-days PSO. The kinetics profiles showed that antigen levels gradually decreased from ≤ 7-days PSO to > 22-days PSO. Both RATs showed excellent specificity and acceptable sensitivity for NP specimens with higher viral loads and for specimens collected within 7-days PSO. Hence, they have the potential to become useful tools for the early detection of SARS-CoV-2. However, because of concerns about false negativity, RATs should be used in conjunction with molecular tests.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1
Cycle threshold value distribution of E, RdRP, and N genes according to the positivity of (A) the AFIAS COVID-19 Ag and (B) the ichromaTM COVID-19 Ag assays. Abbreviations: Ag, antigen; PSO, Pos.; positive; Neg., negative.
Fig 2
Fig 2. Antigen kinetics determined for specimens from 38 COVID-19 patients at different post-symptom-onset periods assessed by two antigen assays according to cut-off index values, the AFIAS COVID-19 Ag and the ichromaTM COVID-19 Ag.
The smoothing splines of both assays showed gradual decrement from the days 1‒7 to days >22, while it was shown that their RdRP gene cyclic threshold values gradually increased or their viral loads decreased. Abbreviations: Ag, antigen; COI, cut-off index; AFIAS, AFIAS COVID-19 Ag (Boditech Med., Chuncheon-si, Gang-won-do, Republic of Korea); ichroma, ichromaTM COVID-19 Ag (Boditech Med.); Ct, cycle threshold.

References

    1. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al.. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro surveillance: bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. 2020;25(3). Epub 2020/01/30. 10.2807/1560-7917.Es.2020.25.3.2000045 - DOI - PMC - PubMed
    1. Hong KH, Lee SW, Kim TS, Huh HJ, Lee J, Kim SY, et al.. Guidelines for Laboratory Diagnosis of Coronavirus Disease 2019 (COVID-19) in Korea. Ann Lab Med. 2020;40(5):351–60. Epub 2020/09/01. 10.3343/alm.2020.40.5.351 - DOI - PMC - PubMed
    1. Centers for Disease Control and Prevention. Overview of Testing for SARS-CoV-2 (COVID-19) [cited 15 December 2020]. In: CDC website [Internet]. Atlanta, GA. https://www.cdc.gov/coronavirus/2019-ncov/hcp/testing-overview.html.
    1. Mak GC, Cheng PK, Lau SS, Wong KK, Lau CS, Lam ET, et al.. Evaluation of rapid antigen test for detection of SARS-CoV-2 virus. Journal of clinical virology: the official publication of the Pan American Society for Clinical Virology. 2020;129:104500. Epub 2020/06/26. 10.1016/j.jcv.2020.104500 - DOI - PMC - PubMed
    1. Albert E, Torres I, Bueno F, Huntley D, Molla E, Fernández-Fuentes M, et al.. Field evaluation of a rapid antigen test (Panbio™ COVID-19 Ag Rapid Test Device) for COVID-19 diagnosis in primary healthcare centres. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2020. Epub 2020/11/16. 10.1016/j.cmi.2020.11.004 - DOI - PMC - PubMed

Publication types

Substances